Acceleration of periosteal bone formation by human basic fibroblast growth factor containing a collagen-binding domain from Clostridium histolyticum collagenase.
Bottom Line: However, repeated dosing is required for sustained therapeutic effect as the efficacy of bFGF decreases rapidly following its diffusion from bone defect sites.The affinity of the fusion protein towards collagen and demineralized bone matrix (DBM) was also confirmed by collagen-binding assays.Taken together, these properties suggest that the CB-bFGF/collagen composite is a promising material for bone repair in the clinical setting.
Affiliation: Department of Orthopedic Surgery, Kitasato University School of Medicine, 1-15-1 Minami-ku Kitasato, Kanagawa, Japan.Show MeSH
Related in: MedlinePlus
Mentions: Two weeks after being grafted onto rat femurs, bFGF/DBM and CB-bFGF/DBM (0.058 nmol bFGF protein) had significantly stimulated periosteal bone formation compared to PBS/DBM [Fig. 4(B)]. In the CB-bFGF/DBM-treated group, bone formation increased in a dose-dependent manner, whereas a plateau in bone formation was reached for bFGF/DBM at 0.058 nmol. New bone volume and bone mineral content in femurs treated with CB-bFGF/DBM (0.29 and 0.58 nmol CB-bFGF) were significantly higher than those of femurs treated with similarly prepared bFGF/DBM [Fig. 4(A–C)].
Affiliation: Department of Orthopedic Surgery, Kitasato University School of Medicine, 1-15-1 Minami-ku Kitasato, Kanagawa, Japan.